Sino Biopharmaceutical Announces Promising Phase I Data on Kylo-0603 at EASL 2026
Key Highlights
- First-in-human data presented at a major international congress: Sino Biopharmaceutical Limited’s wholly-owned subsidiary, Hangzhou Hygieia Biomedical Co., Ltd., presented Phase I clinical data for its innovative drug candidate, Kylo-0603, at the 2026 European Association for the Study of the Liver (EASL) Congress.
- Kylo-0603 – A Novel, Targeted Oral Therapy: Kylo-0603 is the world’s first thyroid hormone receptor-beta (THR-β) small molecule agonist conjugated with GalNAc for specific liver targeting. It is designed to treat metabolic dysfunction-associated fatty liver disease (MAFLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).
Details of the Phase I Clinical Study
- Study Design: The study involved 60 healthy volunteers (mean age: 29.7 years, 50% female) randomized to receive once-daily oral doses of Kylo-0603 (1.2, 2, 4, 8, 12, or 16 mg) or placebo for 14 days, with a 7-day follow-up period.
- Safety and Tolerability: Kylo-0603 showed an excellent safety profile:
- No serious adverse events (AEs) reported.
- No treatment- or dose-related trends in AEs.
- Most AEs were mild (Grade 1), and all treatment-related AEs were Grade 1.
- No gastrointestinal AEs reported in the Kylo-0603 group.
- No significant liver enzyme (ALT) elevations across all dose levels.
- Thyroid hormone levels remained within normal range, with no symptoms or signs of thyroid dysfunction.
- Pharmacokinetics:
- Nonlinear exposure observed.
- Drug concentrations were generally below quantification limits within 8 hours post-dose, with no accumulation over multiple doses.
- Short half-life (0.5 to 1.5 hours).
- Efficacy – Lipid Lowering Effects:
- Kylo-0603 achieved clinically meaningful, placebo-adjusted reductions in LDL-cholesterol at doses of 8 mg, 12 mg, and 16 mg after 15 days of treatment, with the highest reduction (up to 28.5%) seen in the 12 mg cohort.
- Significant reductions also observed in total cholesterol, apolipoprotein B, and triglycerides.
Strategic and Market Implications
- Innovative Mechanism & Market Opportunity: MAFLD affects over 25% of the global adult population and is the leading cause of liver disease worldwide. Kylo-0603’s unique dual-targeting approach (GalNAc for liver specificity and THR-β selectivity) positions it as a potentially best-in-class therapy for MAFLD, MASH, and possibly for weight management.
- Competitive Differentiation: By efficiently delivering a thyroxine-like compound directly to the liver, Kylo-0603 may offer superior efficacy and safety at lower doses, minimizing extrahepatic side effects—a significant advantage over current therapies.
- Upcoming Milestone: Sino Biopharmaceutical plans to initiate a Phase II clinical study for Kylo-0603 within 2026, representing a critical catalyst for the company’s pipeline and future growth.
Implications for Shareholders
- Potential Share Price Catalyst: The positive Phase I data, especially the significant LDL-cholesterol reduction and excellent safety profile, positions Kylo-0603 as a high-value asset in Sino Biopharmaceutical’s pipeline. This news is likely to be viewed positively by investors, given the large unmet medical need in MAFLD/MASH and the limited competition in the oral, liver-targeted THR-β agonist space.
- Future Value Drivers: Progress into Phase II clinical trials could bring further upside and attract strategic partnerships or licensing opportunities.
Board and Management
The announcement was authorized by Chairwoman Ms. Tse, Theresa Y Y, and the Sino Biopharmaceutical board, reflecting strong executive backing for this R&D initiative.
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult with professional advisors before making investment decisions. The information is based on a company announcement dated 27 May 2026 and reflects the data available at that time. Future results may differ materially.
中國生物製藥公佈Kylo-0603第一期臨床數據，或成股價催化劑
重點摘要
- 首個人體數據於國際大型學術會議發表： 中國生物製藥全資子公司杭州海捷亞生物醫藥有限公司，於2026年歐洲肝臟研究協會（EASL）大會發表創新藥物Kylo-0603的第一期臨床數據。
- Kylo-0603－創新靶向口服療法： Kylo-0603為全球首款以GalNAc結構共軛，實現肝臟特異性靶向的甲狀腺激素受體β（THR-β）小分子激動劑，用於治療代謝功能障礙相關脂肪肝病（MAFLD）及其進展型MASH。
第一期臨床研究詳情
- 研究設計： 60名健康志願者（平均年齡29.7歲，女性佔50%）隨機分組，連續14天每日一次口服Kylo-0603（1.2、2、4、8、12或16毫克）或安慰劑，治療結束後跟進7天。
- 安全性及耐受性：
- 未見嚴重不良事件（SAE）。
- 不良事件無劑量或治療相關趨勢。
- 大部分不良事件屬輕微（1級），所有治療相關不良事件亦為1級。
- Kylo-0603組無腸胃道不良事件報告。
- 所有劑量組別的肝酶（ALT）無明顯升高。
- 甲狀腺激素水平大多維持在正常範圍，無功能紊亂症狀。
- 藥代動力學：
- 表現非線性暴露特徵。
- 大部分劑量組於服藥8小時內血漿濃度低於定量下限，無積聚現象。
- 半衰期短（0.5至1.5小時）。
- 療效－降脂效果：
- 8、12及16毫克組於第15日顯著降低低密度脂蛋白膽固醇（LDL-C），最高可達28.5%（12毫克組），具臨床意義。
- 總膽固醇、載脂蛋白B及三酸甘油脂亦顯著下降。
策略及市場啟示
- 創新機制及市場潛力： MAFLD全球患病率超過25%，為肝病主因。Kylo-0603具GalNAc肝臟靶向及THR-β選擇性雙重優勢，有望成為同類最佳療法，亦適用於MASH及體重管理。
- 競爭優勢： Kylo-0603能高效輸送甲狀腺激素類藥物至肝臟，料可在較低劑量下實現更佳療效及安全性，減少肝外副作用，優於現有療法。
- 即將到來的里程碑： 公司計劃2026年內啟動第二期臨床研究，為產品線及未來增長帶來關鍵催化。
對股東的啟示
- 潛在股價催化劑： 第一期數據顯示顯著降脂效應及出色安全性，Kylo-0603有望成為公司高價值資產。考慮到MAFLD/MASH龐大未被滿足的醫療需求及口服肝臟靶向THR-β激動劑競爭有限，料市場反應正面。
- 未來價值增長點： 進入第二期臨床或吸引戰略合作及授權機會，進一步釋放公司價值。
董事會及管理層
公告由董事會主席謝其盈女士及董事會批准，反映公司高層對研發工作的重視。
免責聲明
本文僅供參考，並不構成任何投資建議或要約。投資者應自行研究並諮詢專業意見再作決策。資料根據2026年5月27日公司公告編寫，未來結果或有變化。
